ISSN Print: 2664-7591
ISSN Online: 2664-7605
Impact Factor: RJIF 5.2
IJAN 2024; 6(1): 07-14
www.pharmaceuticaljournal.in
Received: 08-11-2023
Accepted: 11-12-2023

Ranjith Kumar Karunanidhi
Department of Regulatory Affairs, JKKMMRF College of Pharmacy, Komarapalayam, Tamil Nadu, India

Dr. N Senthil kumar
M. Pharm, Ph.D, Principal, JKKMMRF's Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamil Nadu, India

Senthil kumar Balakrishnan
Professor
JKKMMRF's Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamil Nadu, India

Kodali Sirisha
M. Pharmacy, Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Thirucengode, Tamil Nadu, India

Jeganathan B
Department of Regulatory Affairs, JKKMMRF College of Pharmacy, Komarapalayam, Tamil Nadu, India

Tharani S
M. Pharmacy, Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Thirucengode, Tamil Nadu, India

Ayesha Thasneem VM
Department of Regulatory Affairs, JKKMMRF College of Pharmacy, Komarapalayam, Tamil Nadu, India

Corresponding Author:
Ranjith Kumar Karunanidhi
Department of Regulatory Affairs, JKKMMRF College of Pharmacy, Komarapalayam, Tamil Nadu, India

Regulatory requirements: The orphan drugs in various countries

Ranjith Kumar Karunanidhi, Dr. N Senthil Kumar, Senthil Kumar Balakrishnan, Kodali Sirisha, Jeganathan B, Tharani S and Ayesha Thasneem VM

DOI: https://doi.org/10.33545/26647591.2024.v6.i1a.73

Abstract
Regulatory authorities globally have established specific frameworks governing the approval of orphan drugs, crucial for addressing rare diseases that affect a small portion of the population. This comprehensive review article offers a detailed exploration of the distinct regulatory requirements outlined by five prominent bodies: CDSCO, USFDA, EMA, ANVISA, and SFDA. The Central Drugs Standard Control Organisation (CDSCO) in India requires a thorough process for orphan drug designation. Companies requesting permission are required to provide proof of disease prevalence, unmet medical needs, and strong safety and efficacy information. The USFDA, which focuses on illnesses that affect less than 200,000 people, provides tax benefits and expedited reviews for orphan medications in an effort to hasten their development. In Europe, approval of orphan drugs that affect fewer than 5 out of 10,000 people is governed by the European Medicines Agency (EMA). In order to promote innovation in the treatment of rare diseases, EMA has established a framework that offers fee reductions, protocol support, and ten years of market exclusivity. Brazil's National Health Surveillance Agency (ANVISA) requires comprehensive documentation for orphan drug approval. Companies must demonstrate evidence of disease rarity, safety, efficacy, and, in some cases, ongoing clinical trials. Similarly, the Saudi Food and Drug Authority (SFDA) in Saudi Arabia oversees drugs for conditions impacting less than 5 in 10,000 individuals, necessitating detailed justifications and post-designation compliance.
Every regulatory agency upholds specific standards for the designation of drugs as orphans, diverse application processes, and a range of incentives to encourage the development of treatments for uncommon diseases. Pharmaceutical companies navigating the complex orphan medication approval process must have a thorough understanding of various regulatory environments.

Keywords: Orphan drugs, regulatory requirements, central drugs standard control organisation (CDSCO), USFDA, European medicines agency (EMA), brazil's national health surveillance agency (ANVISA), Saudi food and drug authority (SFDA)

Introduction
Orphan drugs, sometimes referred to as orphan medicinal products, are medications developed especially to address rare diseases. Due to their low commercial potential, these illnesses are often referred to as orphan diseases that affect a small percentage of the population and are usually ignored by the pharmaceutical industry. Global regulatory agencies have set certain standards for orphan drug approval, recognising the need for medicines for these uncommon illnesses [1]. An overview of the regulations outlined by five major regulatory agencies, the CDSCO, USFDA, Brazilian, European Emergency, and SFDA will be given in this article.
In recent years, there has been a standard shift in recognizing the importance of orphan drugs, not only for their potential to alleviate the suffering of patients with rare diseases but also for their broader impact on the pharmaceutical industry. The development of orphan drugs not only represents a lifeline for those afflicted by these conditions but also demonstrates the pharmaceutical industry's commitment to addressing unmet medical needs across diverse patient populations. Despite their critical role, the development of orphan drugs poses unique challenges.

The limited patient population makes conducting clinical trials and gathering sufficient data more challenging, often requiring innovative approaches to demonstrate safety and efficacy. Additionally, the high development costs relative to a smaller market size create financial hurdles for pharmaceutical companies, necessitating tailored regulatory frameworks that incentivize and support their development [2].

The approval of orphan drugs requires specialized regulatory pathways designed to accommodate these unique challenges. These pathways aim to facilitate the development, evaluation, and approval of orphan drugs while balancing the need for strict safety and efficacy standards. Understanding these regulatory pathways established by different regulatory bodies is vital for pharmaceutical companies striving to bring innovative therapies to patients affected by rare diseases [1]. By acknowledging the transformative potential of orphan drugs, the challenges in their development, and the evolving landscape of regulatory frameworks tailored to address these needs, this article aims to provide a comprehensive overview of the complex processes governing the approval of orphan drugs by esteemed regulatory bodies worldwide.

CDSCO (Central Drugs Standard Control Organization) Is the regulatory body responsible for the approval of drugs in India. In order to obtain orphan drug designation in India, a pharmaceutical company must submit an application to the Drug Controller General of India (DCGI). The company must provide evidence of the disease prevalence and unmet medical need, as well as data on the proposed drug's safety and efficacy. Once orphan drug designation is granted, the company can apply for market authorization, following the standard regulatory pathway [3].

The USFDA (United States Food and Drug Administration) has a well-established framework for the approval of orphan drugs. In order to qualify for orphan drug designation in the United States, a drug must be intended to treat a disease or condition that affects fewer than 200,000 individuals in the country. The drug must also demonstrate a significant advantage over existing treatments or show promise in treating a rare disease for which there are no approved therapies. Once approved as an orphan drug, the drug developer is eligible for certain incentives, such as tax credits and market exclusivity, as well as a streamlined regulatory review process [4].

In Europe, the EMA (European Medicines Agency) Governs the approval of orphan drugs. The EMA grants orphan drug designation to products that aim to treat conditions affecting fewer than five in 10,000 individuals in the European Union (EU). Similar to the USFDA, the drug must either provide a significant benefit over existing treatments or address a rare disease with no available therapies. Orphan drug designation in the EU allows for specific incentives, including fee reductions, protocol assistance, and ten years of market exclusivity [4].

Brazil, through its National Health Surveillance Agency (ANVISA)
Has established its own regulatory requirements for orphan drug approval. In Brazil, orphan drugs are referred to as "drugs for rare diseases." To obtain approval, a company must submit an application to ANVISA demonstrating evidence of the disease's rarity and unmet medical need. The drug must also present favourable safety and efficacy data. Once approved, drugs for rare diseases are subject to special regulations regarding prescription, dispensing, and pharmacovigilance [5].

In Saudi Arabia, the Saudi Food and Drug Authority (SFDA)
Oversees the approval and regulation of orphan drugs, known locally as "drugs for rare diseases." Companies seeking approval must submit an application to the SFDA, providing evidence of the rarity of the disease and the lack of available treatments, alongside robust data on the drug's safety and efficacy. Upon obtaining approval, these drugs are governed by specific rules that cover aspects such as prescribing, dispensing, and ongoing safety monitoring to ensure continued compliance with SFDA standards [6].

Objective
This article objectives to provide a comprehensive and comparative overview of the regulatory pathways for orphan drug approval, elucidating the specific criteria and approval processes across multiple regulatory bodies including CDSCO, USFDA, EMA, ANVISA (Brazil), and SFDA. By highlighting the incentives, benefits, and distinct compliance obligations offered by each regulatory authority, facilitate an understanding of the global landscape governing orphan drug development. Furthermore, this review aims to underscore the significance of these regulatory frameworks in addressing unmet medical needs for rare diseases, outlining the impact on patient access to treatments. By delving into post-approval obligations and compliance requirements.

India - CDSCO
Regulatory Framework and Orphan Drug Designation Criteria
The Central Drugs Standard Control Organization (CDSCO) in India holds a crucial role in the regulation and approval of pharmaceutical products, ensuring their safety and efficacy for the Indian population. Over recent years, the CDSCO has shown an improved focus on orphan drugs, which are specialized medications developed to treat rare diseases affecting a small portion of the population. Given the rarity of these diseases, orphan drugs have unique regulatory requirements, and the CDSCO has established a framework to facilitate their development and approval.
Orphan drugs, generally defined as treatments for diseases affecting fewer than 200,000 people in the United States (criteria that are often adopted in India), receive special attention from regulatory agencies. The CDSCO, like its counterparts in other countries, offers incentives to pharmaceutical companies to encourage the development of these drugs. These incentives may encompass financial support, tax credits, and extended market exclusivity, but to gain approval in India, orphan drugs must adhere to strict regulatory requirements [7].

Orphan Drug Approval Process under CDSCO
The approval process for orphan drugs in India involves several critical steps

1. **Extensive Research and Clinical Trials:** Pharmaceutical companies pursuing approval for

orphan drugs in India must conduct comprehensive preclinical and clinical research to demonstrate the safety and efficacy of their products. This involves well-designed clinical trials involving patients with rare diseases, robust evidence of the drug's effectiveness, and a thorough understanding of potential risks and side effects. These clinical trials should adhere to good clinical practices (GCP) and be precisely documented. Furthermore, the CDSCO may consider additional factors, such as the rarity and severity of the disease, the availability of alternative treatments, and the overall public health impact. This approach allows for a more flexible evaluation of orphan drug applications, with manufacturers required to present a compelling case that their drug is not only safe and effective but also addresses an unmet medical need [8].

2. **Manufacturing and Quality Control Evaluation:** The CDSCO conducts a thorough review of the manufacturing and quality control procedures for the drug. This is done to ensure that the medication can be consistently produced to meet the necessary quality standards, ensuring patient safety. Manufacturing facilities may be inspected, and the company's ability to maintain product quality over time is assessed [8].
3. **Marketing Approval:** Once the CDSCO is satisfied with the clinical, manufacturing, and quality control data, it may grant marketing approval for the orphan drug. This approval typically comes with certain post-marketing requirements, including ongoing safety monitoring and the collection of additional data to confirm the drug's long-term benefits and risks [9].
4. **Pricing and Reimbursement Flexibility:** Orphan drugs, due to their high development costs and limited patient population, are often more expensive than conventional drugs. The CDSCO may work collaboratively with manufacturers to establish pricing models that strike a balance between affordability and the need to recoup development costs [9].

In 2019, the Government of India introduced the New Drugs and Clinical Trials (NDCT) Rules, which extend to new drugs, investigational new drugs, bioavailability/bioequivalence studies, clinical trials, and Ethics Committees. Under these rules, drugs with orphan designation are subject to the same regulatory procedures as other drugs. Sponsors of orphan drugs are required to submit applications for drug approval to the Central Licensing Authority, led by the DCG(I) within the CDSCO.

The NDCT Rules 2019 provide specific relaxations for orphan drugs, including

a) Exemption from the requirement for a local clinical trial.
b) A fast-track and accelerated approval process.
c) Provision for an expedited review process after clinical development.
d) Exemption from the application fee for conducting a clinical trial [10].

If the DCG (I) is content with the submitted documents, they may grant permission to the sponsors. This regulatory framework aims to expedite the development and approval of orphan drugs in India, recognizing their unique challenges and the critical need for treatments for rare diseases [11].

Brazil - ANVISA (National Health Surveillance Agency)
Regulatory Framework and Orphan Drug Approval in Brazil

In Brazil, through its National Health Surveillance Agency (ANVISA), specialized regulatory requirements exist for the approval of orphan drugs, referred to as "drugs for rare diseases." The ANVISA plays a pivotal role in promoting the protection of the population's health by overseeing the regulatory aspects of drug approvals.

Institutes involved in the registration process are

1. Ministry of Health
2. **ANVISA (Brazilian Health Surveillance Agency):** promote the protection of the health of the population through the sanitary control of the production and consumption of products and services that are under sanitary investigation, including the environments, progressions, inputs, and technologies related to them.
3. **GGMED (General Management of Drugs and Biological Products):** Coordinates, supervises, controls, and evaluates the activities related to the registration and post-registration, inspection, norms, and standards establishments, quality, safety, and efficacy concerning the sanitary surveillance of active pharmaceutical inputs, drugs, biological products and clinical research in drugs involving humans.

In the case of drugs already registered in other countries, a technical assessment report of the product, issued by the respective regulatory authorities, should be submitted, when available.

In the case of imported drugs, the suppression of quality control in Brazil is allowed, provided that the quality control is performed by the manufacturer of the drug and a summary report of the operation qualification of the transport.

In cases where the company applying for registration does not have the complete clinical development of the rare disease drug with an active pharmaceutical ingredient (API) new in the country, a medical report may be submitted to ANVISA.

Safety and efficacy reports may be accepted when phase II studies are completed and phase III studies are ongoing, or without the submission of phase III clinical studies, when the conduct of these studies is not viable.

ANVISA's Approval Process for Drugs for Rare Diseases

The registration process for drugs for rare diseases in Brazil follows a structured approach

Phase 1: Approval of Clinical Trials

- Request a pre-submission meeting for Drug Development and Clinical Trials with ANVISA (Brazilian Health Surveillance Agency).
- Conduct the pre-submission meeting within 60 days of the request.
- Submit Drug Development and Clinical Trials documentation to ANVISA using a specific subject code.

- ANVISA assesses the documentation within 30 days of submission and issues a notification of requirements or a conclusive opinion.
- If necessary, hold a meeting to discuss the requirements.
- Comply with the requirements within 30 days of notification.
- ANVISA evaluates compliance within 30 days after submission.

Phase 2: Certification of Good Manufacturing Practices (GMP)

- If interested in manufacturing drugs for rare diseases in Brazil, request GMP certification for the manufacturing plants. The plants must comply with GMP for Drugs legislation.
- Wait for ANVISA to publish its decision regarding GMP certification within 120 days after a factory inspection.
- For importers and distributors, obtain a Certificate of Good Distribution and Storage Practices, following the same standards and requirements as GMP for Drugs.

Phase 3: Approval of Clinical Trials with International Comparator Drugs

- ANVISA may allow the use of an international comparator drug registered with another regulatory authority when there is an agreement and similarity of sanitary measures.
- The registration dossier must include a request to use the international comparator drug, and the package insert of the drug to be registered must match the international comparator drug in terms of indications, route of administration, and posology.

Documents Required for Registration:

Administrative Documents

1. Application forms FP1 and FP2 completed and signed.
2. Proof of payment of ANVISA fees from the Health Surveillance (TFVS).
3. Status of the medicinal product (imported or locally manufactured).
4. Good Manufacturing Practice (GMP) certificate issued by ANVISA or a copy of the request for GMP inspection.
5. Copy of GMP certificate in the country of origin for imported products.
6. Proof of registration in the country of origin for imported drugs (CPP).
7. Declaration signed by the legal representative committing to submit required additions within 10 days after registration submission.
8. Copy of the minutes of the pre-submission meeting held with ANVISA.

Technical Documents for New Drugs

1. Documentation on the active pharmaceutical ingredient.
2. Quality control of excipients by the manufacturer of the finished product.
3. Quality control of primary and secondary packaging materials.
4. Technical report on the formulation's development.
5. Description of manufacturing and packaging processes.
6. Process validation report.
7. Product quality control performed.
8. Stability studies of the finished product.
9. Diluent/reconstituent solutions.
10. Safety and effectiveness report.
11. Technical justification for rare disease registration.

Technical Documents for Biological Products

1. Technical justification for product registration.
2. Barcodes (GTIN) or identification and security mechanisms as per current legislation.
3. Copy of the national, international, or internal compendium with specifications for the finished biological product.
4. Product technical report.
5. Therapeutic experimentation report.
6. Pharmacovigilance report.
7. Immunogenicity study report.
8. Pharmacovigilance plan and risk minimization plan.
9. Manufacturing documentation and quality control.

Additional Administrative Documents for Biological Products

1. History of the registration situation in other countries (if applicable).
2. Proof of registration in the origin country of the biological product.
3. Names and addresses of all manufacturers involved in production [12].

Timelines

- ANVISA takes up to 90 days to analyse the registration dossier.
- Registration validity is 10 years.
- Revalidation should occur 180 days before the registration's validity date.
- GMP/GDP/GSP certificates are valid for 2 years.
- Plant inspections for GMP certificates take up to 1 year [13].

USFDA (United States Food and Drug Administration)

Regulatory Framework and Orphan Drug Approval in the United States

In the United States, the FDA has launched an initiative to overhaul the approval process for safe and effective treatments aimed at rare diseases. The primary objective of this program is to enhance the efficiency, scientific rigor, predictability, and modernization of procedures, with a specific focus on the issuance of Orphan Drug Designations by the Office of Orphan Products Development (OOPD). The primary goal is to provide greater confidence to sponsors while simplifying and expediting the processes associated with the development of orphan drugs.

USFDA's Approach to Orphan Drug Approval

Objective 1: Clearing the Backlog of Older Designation Requests

1. The FDA set about on a mission to expedite the review of all orphan drug designation requests pending for over 120 days within a 90-day timeframe.
2. To achieve this, a dedicated team known as the "Backlog SWAT Team," comprised of experienced OOPD reviewers, was formed, with a primary emphasis on addressing the oldest requests as a priority.

3. The introduction of a more efficient Designation Review Template was aimed at enhancing uniformity, efficiency, and predictability.
4. Responsibilities unrelated to designation and grant-specific duties for other reviewers were minimized to allow the review teams to focus on core activities.
5. Collaborative endeavours with FDA's Medical Product Centres were initiated through the CDER-CBER Orphan Designation Pilot Project.
6. For requests related to rare paediatric diseases (RPD), a collaborative approach was established in coordination with the Office of Paediatric Therapeutics (OPT).
7. The secondary review of Freedom of Information Act (FOIA) requests was shifted to the FOIA office.
8. Continuous monitoring of progress and transparent reporting to the public were consistently upheld.

Objective 2: Timely Responses to New Designation Requests

1. The FDA made a commitment to respond to 100 percent of new orphan drug designation requests within 90 days of their receipt, with a sustained adherence to this 90-day timeline.
2. To ensure a standardized approach to the regulation of orphan products, the establishment of the "FDA Orphan Products Council" was a significant step to address scientific and regulatory aspects.
3. Organizational restructuring efforts were undertaken to maximize expertise and optimize workload efficiency.
4. The inter-centre consult process, initially developed for combination products, was leveraged to devise a streamlined process for consistent and punctual orphan consultations.
5. The centralization of orphan exclusivity review and determinations was initiated.
6. The improvement and automation of information technology infrastructure, particularly for administrative processes, were systematically pursued.
7. A web-based training program for sponsors was developed to enhance the quality of submissions.
8. Grant programs, including the Orphan Products (OPD) Grant Program and the Paediatric Device Consortia (PDC) Grant Program, underwent revisions aimed at efficient monitoring and reporting.
9. Strategies to reduce the overall workload were implemented, including adjustments to the frequency of Orphan Cluster and Rare Disease Council meetings.
10. Outreach activities and discretionary projects were limited to those considered of utmost significance.
11. The introduction of a "Tracking Dashboard" was designed to monitor and facilitate efforts in line with the new designation goals, with increased reporting frequency.

This comprehensive strategy is designed to expedite the review and approval of orphan drugs, while ensuring a consistent and rigorous evaluation process. It underscores the FDA's commitment to addressing the unique challenges posed by treatments for rare diseases and supporting the development of safe and effective therapies for patients in need [14].

In addition to the FDA's initiatives, the passage of the Orphan Drug Act by the U.S. Congress in 1983 has led to the FDA's approval of numerous drugs designed to treat rare diseases. Pharmaceutical companies seeking orphan drug designation and meeting specific criteria are eligible for various incentives, including tax credits for qualified clinical testing, waiver of user fees for the Prescription Drug, and the potential for 7 years of market exclusivity following approval. Furthermore, drugs or products meeting the criteria for rare paediatric disease designation may receive priority review vouchers from the FDA under Section 529 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [15].

The application for orphan drug designation can be made through three different avenues

1. Utilizing the CDER Next Gen portal.
2. Sending a direct email to orphan@fda.hhs.gov.
3. Mailing the application directly to the Office of Orphan Products Development (OOPD) [16].

EMA (European Medicines Agency)

Regulatory Framework and Orphan Drug Approval in the European Union

The European Medicines Agency (EMA) is a crucial authority responsible for regulating and approving orphan drugs in the European Union (EU). These drugs are specifically developed to address rare diseases, and the EMA's framework is accurately designed to update their development and approval, addressing the distinct challenges associated with rare diseases [15].

The EMA follows a structured approach to oversee orphan drug development and approvals

1. **Orphan Designation Application:** The initiation of the approval process for orphan drugs necessitates pharmaceutical developers to submit an orphan designation application to the EMA. This application serves as the primary step in determining the drug's eligibility for orphan status, with a primary focus on its intended use in diagnosing, preventing, or treating diseases that affect fewer than 5 in 10,000 individuals in the EU.
2. **Incentives for Orphan Designation:** Upon securing orphan designation, pharmaceutical developers gain access to a diverse range of incentives. These incentives encompass fee reductions for regulatory activities, granting a decade of market exclusivity, and extending the exclusivity period by two years for drugs equipped with an agreed paediatric investigation plan. Additionally, micro, small, and medium-sized enterprises (MSMEs) can take advantage of administrative and procedural support and fee reductions.
3. **Development Process:** The development process for orphan drugs is characterized by comprehensive preclinical testing, emphasizing safety, potential efficacy, and a thorough understanding of the drug's mechanism of action. While clinical trials are a central component, they may involve smaller sample sizes due to the uncommonness of the diseases, all while following to the rigorous standards of Good Clinical Practice (GCP).
4. **Quality and Manufacturing Standards:** The EMA exactly ensures that drug manufacturing follows the challenging standards of Good Manufacturing Practice (GMP). This oversight includes regular inspections to

confirm compliance and guarantee the consistent production of high-quality products.

5. **Marketing Authorization Application (MAA):** Upon gathering the necessary preclinical and clinical data, drug developers progress to submit a Marketing Authorization Application (MAA) to the EMA. The MAA encompasses comprehensive information relating to the drug's safety, efficacy, and quality.
6. **Committee for Orphan Medicinal Products (COMP) Opinion:** The Committee for Orphan Medicinal Products (COMP) is of paramount importance, providing a well-informed opinion grounded in scientific assessment. This opinion plays an indispensable role in the approval process and is subsequently reviewed by the Committee for Medicinal Products for Human Use (CHMP).
7. **Conditional Marketing Authorization:** Conditional marketing authorization, granted by the CHMP, is particularly relevant in cases where there is a recognized unmet medical need and the benefits of the drug outweigh potential risks. This conditional approval expedites the drug's availability to patients by permitting its marketing while further data is collected.
8. **Post-Marketing Commitments:** Conditional approvals often require post-marketing commitments, which may include conducting supplementary studies to validate therapeutic benefits, ensuring long-term safety monitoring, and gathering additional data.
9. **Pricing and Reimbursement:** Pharmaceutical developers may need to engage in negotiations with individual EU member states to establish pricing and reimbursement arrangements. This process is essential to ensure patient access to these drugs at reasonable prices [14, 17].

Notably, it is crucial to highlight that sponsors are no longer obligated to submit a notification of intent for filing an orphan drug application for designation to the EMA. Instead, sponsors should obey specific procedures for the review of orphan designation applications by the EMA's Committee for Orphan Medicinal Products (COMP), which controls a network of experts for evaluation. This streamlined process ensures a maximum 90-day timeframe from validation [18].

SFDA (Saudi Food and Drug Authority)

The Saudi Food & Drug Authority (SFDA) provides a specialized framework for the approval of orphan drugs, which are medicinal products intended for the diagnosis, prevention, or treatment of life-threatening or very serious conditions that are rare and affect not more than 5 in 10,000 individuals in the Kingdom of Saudi Arabia [19].

Regulatory Framework and Orphan Drug Approval in Saudi

1. **SFDA's Orphan Drug Framework:** The SFDA oversees the implementation of regulatory policies for drugs treating rare diseases. Its guidance on orphan drug designation (ODD) is aimed at ensuring access to medications for all, especially those with rare diseases that are often overlooked in the market.
2. **Criteria for Orphan Drug Designation:** To qualify for ODD, a drug must address a condition affecting fewer than 5 in 10,000 individuals in Saudi Arabia, or it must not be financially viable without incentives. The application must provide a detailed justification for the drug's intended orphan use, supported by clinical and scientific data.
3. **The process of Orphan Designation**

- The sponsor uses Sdr.drug@sfda.gov.sa to send a request to the SFDA informing them of their intention to submit an application for orphan drug designation.
- Meeting with sponsor for pre-submission SFDA
- Sponsor submission of an application for orphan drug designation (ODD)
- SFDA validation of the application
- Evaluation and suggestions for orphan drug designation
- The final decision to be made
- The public summary of ODD is posted on the SFDA website.

4. **Application and Approval Process:** An electronic application for ODD should be submitted to the SFDA, detailing one orphan indication per drug or dosage form. The SFDA reviews the application to assess the condition's seriousness, the drug's potential benefit, and the prevalence of the condition in Saudi Arabia.
5. **Post-Designation Requirements:** Once designated, orphan drugs must be supported by annual development reports to maintain their status. The SFDA requires these reports to ensure continuous monitoring of the drug's development progress.
6. **Incentives for Designated Orphan Drugs:** The SFDA provides various incentives for drugs that receive ODD. These may include priority review, regulatory advice, potential fee waivers, and marketing exclusivity for a period following approval.
7. **Maintenance and Compliance:** To maintain the ODD, sponsors must comply with the SFDA's ongoing requirements, including the submission of annual reports on the drug's development status. The SFDA may revoke the designation if the drug is later found ineligible or if the sponsor fails to meet the post-designation requirements.
8. **Documentation and Annexes:** The SFDA's guidance document includes annexes with templates for applications, which outline the required documentation for ODD submission. These annexes detail the format and content of the application, including the description of the condition, medical plausibility, seriousness justification, prevalence data, and information on the drug's development stage.
9. **Transparency and Public Summary:** Upon granting ODD, the SFDA publishes a summary of the designation to ensure transparency. This public document includes the drug's name, intended use, and a brief description of the condition it treats.
10. **SFDA's Right to Request Further Information:** The SFDA retains the right to request additional information or clarification to adequately assess the safety, efficacy, and quality of the orphan drugs [6, 19].

Table 1: Comparing the regulatory requirements for orphan drug approval among USFDA, EMA, SFDA, CDSCO, and ANVISA

Aspect	United States Food and Drug Administration (USFDA)	European Medicines Agency (EMA)	Saudi Food and Drug Authority (SFDA)	Central Drugs Standard Control Organization (CDSCO)	National Health Surveillance Agency (ANVISA)
Criteria	<200,000 individuals or unviable costs	<5 in 10,000 individuals in EU	<5 in 10,000 individuals in Saudi Arabia	Small population; specific criteria for rare diseases	65 people in every 100,000 Individuals based on official national data
Designation Process	Next Gen portal, email, mail to OOPD	Submission; no intent notification	Email request, validation, review	Thorough submission process; specific guidelines	Rigorous documentation, evaluations
Incentives	Tax credits, fee waivers, exclusivity	Fee reductions, 10-year exclusivity	Priority review, fee waivers, exclusivity	Fee reductions, expedited reviews, waivers	Fee reductions, priority review, exclusivity
Post-Designation	Annual reports, compliance	Post-marketing commitments, monitoring	Annual reports, compliance with requirements	Compliance, annual development reports	Compliance, additional data when necessary

Regulatory Challenges in Orphan Drug Approval

Orphan drug development faces several unique regulatory challenges, impeding the path to approval and subsequent patient access. The foremost challenge lies in the limited patient population available for clinical trials, often resulting in difficulties in conducting statistically significant studies to demonstrate efficacy and safety. Additionally, the high costs associated with orphan drug development present a substantial barrier, as pharmaceutical companies may be deterred by the financial risks involved, considering the constrained market size and potential return on investment. Moreover, the heterogeneity across regulatory frameworks globally poses a significant challenge. Varying definitions of rare diseases, differing eligibility criteria, and divergent approval processes among regulatory bodies complicate the harmonization of orphan drug regulations, leading to increased complexities for drug developers operating across multiple jurisdictions [20].

Future Directions and Evolving Regulatory Trends

Despite these challenges, several emerging trends and future directions in orphan drug regulation aim to address these hurdles and foster innovation in the field:

1. **Adoption of Adaptive Regulatory Approaches:** Regulatory bodies are increasingly embracing adaptive pathways, allowing for more flexibility in trial designs, including adaptive trial designs, real-world evidence, and surrogate endpoints. These approaches streamline the approval process and enable more efficient use of limited patient populations [21].
2. **International Collaboration and Harmonization:** Efforts toward international collaboration and regulatory harmonization are gaining authority. Initiatives like the International Council for Harmonization (ICH) aim to standardize requirements and procedures globally, facilitating smoother orphan drug development and approvals across jurisdictions [22].
3. **Advancements in Precision Medicine and Technology:** With advancements in precision medicine, including genomics, biomarkers, and innovative therapies like gene and cell therapies, regulators are exploring novel evaluation methods to accommodate these cutting-edge treatments, paving the way for personalized orphan drug development [23].
4. **Enhanced Patient Engagement and Advocacy:** Regulatory agencies are increasingly recognizing the importance of patient engagement. Encouraging patient involvement in decision-making processes ensures that regulatory frameworks align with patient needs and priorities, fostering a more patient-centric approach to orphan drug development [24].
5. **Addressing Economic and Access Challenges:** Efforts to address the economic aspects of orphan drugs involve exploring innovative pricing models, cost-sharing initiatives, and reimbursement strategies to ensure equitable access while maintaining incentives for continued research and development [21].

Discussion

The regulatory landscape surrounding orphan drugs is a multifaceted ecosystem, evident through the intricate pathways established by different regulatory authorities globally. Within India, the Central Drugs Standard Control Organization (CDSCO) necessitates a rigorous evaluation process emphasizing comprehensive research and stringent clinical trials. This demands extensive data substantiating safety, efficacy, and the unparalleled need for treating rare diseases. In contrast, Brazil's National Health Surveillance Agency (ANVISA) requires exhaustive documentation, particularly stringent for rare disease drug registrations, ensuring a thorough evaluation before approval.

The United States Food and Drug Administration (USFDA) stands out with a comprehensive framework offering a spectrum of incentives, including tax credits and expedited review processes upon orphan drug designation. This not only fosters innovation but also accelerates the accessibility of treatments for rare diseases. Meanwhile, the European Medicines Agency (EMA) orchestrates a meticulous approval process, granting incentives while emphasizing disease rarity and the drug's effectiveness.

Moreover, the Saudi Food & Drug Authority (SFDA) implements specialized frameworks ensuring continual compliance and meticulous post-marketing reporting for designated orphan drugs, underlining the rarity and severity of conditions. While each regulatory body has unique criteria and approaches, a common thread prevails - an unwavering commitment to ensuring the safety, efficacy, and accessibility of treatments for rare diseases. These regulatory frameworks aim to mitigate the challenges posed by limited patient populations, financial barriers, and the complexity of developing drugs for rare conditions.

Yet, challenges persist, including the high developmental costs of orphan drugs and the scarcity of patients for robust

clinical trials. Regulatory heterogeneity across jurisdictions further adds complexity. However, promising trends in regulatory evolution demonstrate adaptability. Initiatives such as adaptive regulatory approaches, collaborative international efforts, advancements in precision medicine and technology, patient engagement strategies, and sustainable solutions are shaping the future of orphan drug regulation. These trends signify a transition towards patient-centred, innovative, and harmonized regulatory pathways, ensuring a more efficient and equitable environment for orphan drug approvals.

Conclusion

In conclusion, the diverse regulatory approaches in CDSCO, ANVISA, USFDA, EMA, and SFDA collectively prioritize addressing the unmet needs of patients with rare diseases. Challenges persist, including limited patient populations for clinical trials, financial barriers, and regulatory heterogeneity globally. However, the evolving regulatory landscape demonstrates promising trends and initiatives. Adaptive regulatory approaches, international collaborations, advancements in precision medicine, enhanced patient engagement, and sustainable strategies are pivotal in shaping future orphan drug regulations. These trends emphasize a shift towards patient-centricity, innovation, and regulatory harmonization, fostering an efficient and equitable environment for orphan drug approvals. As these regulatory frameworks evolve, their collective goal remains steadfast: ensuring timely access to safe and effective treatments for individuals affected by rare diseases. By championing advancements, fostering innovation, and aligning global efforts, these regulatory pathways strive to bridge the gap and meet the critical needs of patients with rare diseases worldwide.

References

1. Pandore Aniket R, Sonawane Sonali S, Rodhe Abhijeet R. A Review of an Orphan Drug.
2. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Reviews Drug Discovery. 2010 Dec;9(12):921-9.
3. MS J. Regulatory Overview on Rare Diseases and Orphan Drugs in India. International Journal of Pharmaceutical Research (09752366); c2020 Jan, 2.
4. Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: Development trends and strategies. Journal of Pharmacy and Bioallied Sciences. 2010 Oct;2(4):290.
5. Borin MC, Barbosa MM, Pereira CO, Martins CR, Dos Reis DP, Ribeiro GJ, *et al*. Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022. Global Health Economics and Sustainability. 2023 Aug;22:0995.
6. Balkhi B, Almuaither A, Alqahtani S. Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union. Saudi Pharmaceutical Journal. 2023 Sep 1;31(9):101738.
7. https://pharmaboardroom.com/legal-articles/orphan-drugs-rare-diseases-india.
8. George B, Kulkarni SK, Kshirsagar NA. Regulatory Requirements and Quality Standards in India's Clinical Trials Journey. Drug Discovery and Drug Development: The Indian Narrative; c2021. p. 283-302.
9. Gahilod RS, Veeranna B, Thakre S. Orphan Drug Development Policies in India and the United States: A Comparison. Indian Journal of Pharmaceutical Education and Research. 2023 Apr 1;57(2):329-36.
10. Ministry of Health and family Welfare, Government of India. Notification for the New Drugs and Clinical Trial Rules 2019 [Document]. Mar. Available from; c2021 https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdfdocuments/NewDrugs_CTRules_2019.pdf, accessed on January 4, 2022.
11. Gupta NV, Ohan Reddy CM, Reddy KP, Kulkarni RA, Shivakumar HG. Process of Approval of New Drug in India with Em Phasis on Clinical Trials. Marketing. 2012 Mar;6:8.
12. https://globalregulatorypartners.com/wp-content/uploads/Orphan-Drug-Registration-in-Brazil-anvisa-global-regulatory-partners-_Final-pdf.pdf
13. Borin MC, Barbosa MM, Pereira CO, Martins CR, Dos Reis DP, Ribeiro GJ, *et al*. Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022. Global Health Economics and Sustainability. 2023 Aug 22:0995.
14. Thaker Z, Jethva K, Bhatt D, Zaveri M, Deshpande S. Orphan drugs: Overview and regulatory review process. Int. J. Pharm. Sci. Res. 2019;10:505-18.
15. Prabha PK, Choudhary G, Prakash A, Medhi B. Drug approval in Rare Disease.
16. Commissioner Office of the Orphan Products Development. FDA. Office of Orphan Products Development [Webpage]. 2021. Available from: https://www.fda.gov/about-fda/office-clinical-policy-and-programs/office-orphan-products-development, accessed on January 4; c2022.
17. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview
18. European Medicines Agency. Committee for Orphan Medicinal Products (COMP) [Webpage]; c2018. Available from: https://www.ema.europa.eu/en/committees/committee-orphan-medicinal-products-comp, accessed on January 4; c2022.
19. https://www.sfda.gov.sa/sites/default/files/2023-06/OrphanDrugDesignation.pdf
20. Bouwman ML, Sousa JJ, Pina ME. Regulatory issues for orphan medicines: a review. Health Policy and Technology. 2020 Mar 1;9(1):115-21.
21. Bagley N, Berger B, Chandra A, Garthwaite C, Stern AD. The Orphan Drug Act at 35: observations and an outlook for the twenty-first century. Innovation policy and the economy. 2019 Jan 1;19(1):97-137.
22. Epps C, Bax R, Croker A, Green D, Gropman A, Klein AV, *et al*. Global regulatory and public health initiatives to advance pediatric drug development for rare diseases. Therapeutic Innovation & Regulatory Science. 2022 Nov;56(6):964-75.
23. Subbiah V. The next generation of evidence-based medicine. Nature medicine. 2023 Jan;29(1):49-58.
24. Young A, Menon D, Street J, Al-Hertani W, Stafinski T. Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet Journal of Rare Diseases. 2017 Dec;12(1):1-4.